Disease relevance of Ciprostene

• Ten patients with peripheral vascular disease and claudication received ciprostene (titrated to 120 ng/kg/min) infused over 8 hours 1 day per week for 4 consecutive weeks [1].
• In patient #5 with a history of arrhythmias, the last ciprostene infusion had to be discontinued at 4.5 hours due to arrhythmias but his data were included into the evaluation [2].
• When patients were characterized according to their clinical status, these differences were accounted for by patients with unstable angina receiving ciprostene [3].
• In contrast, coronary artery stenoses in patients receiving ciprostene (n = 12) measured 83 +/- 3% before PTCA, 31 +/- 4% after PTCA and 55 +/- 9% at 6 month, being still significantly different from pre-PTCA value (P less than 0.05) [3].

High impact information on Ciprostene

• Two other PGI(2) analogs, ciprostene and dehydro-15-cyclohexyl carbaprostacyclin (both 10(-6) M), significantly inhibited fibroblast migration to fibronectin [4].
• During infusion of ciprostene, consistent changes in blood pressure and heart rate did not occur [5].
• High-performance liquid chromatography method for the separation of isomers of 9 beta-methylcarbacyclin (ciprostene) and the analysis of pharmaceutical samples [6].
• The effect of the stable prostacyclin analog ciprostene on hemodynamic parameters, platelet aggregation and clot dissolution was examined in the sodium pentobarbital anesthetized cat [7].

Biological context of Ciprostene

• Hemodynamic and platelet aggregation effects were measured in 5 cats following infusion of 5, 10, 20, 40 and 80 micrograms/kg/min of ciprostene [7].

Analytical, diagnostic and therapeutic context of Ciprostene

• Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty [3].

References